Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Active Diffuse Cutaneous Systemic Sclerosis Extension Study
NCT05149768Phase 2Completed
- Start
- Feb 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in diffuse cutaneous systemic sclerosis (dcSSc). Primary endpoint: modified Rodnan Skin Score at 48 weeks. Started Feb 2024; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT05149768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05149768.